PCSK9-INHIBITORS: IDENTIFICATION OF ELIGIBLE PATIENTS FROM REGIONAL ADMINISTRATIVE HEALTHCARE DATABASES

被引：0
|
作者：
Andretta, M. [1 ]
Menti, A. M. [1 ]
Polini, M. [1 ]
Degli Esposti, L. [2 ]
Bilato, C. [3 ]
Zambon, A. [4 ]
Scroccaro, G. [5 ]
机构：
[1] Coordinamento Reg Unico Farmaco, Verona, Italy
[2] CliCon Srl, Ravenna, Italy
[3] ULSS 5, Ovest Vicentino, Arzignano, Italy
[4] Univ Padua Polyclin, Padua, Italy
[5] Veneto Reg, Venice, Italy
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1796
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV125
引用
收藏
页码：A659 / A659
页数：1
相关论文
共 50 条
  • [1] Third generation PCSK9-inhibitors
    Laufs, Ulrich
    Blueher, Matthias
    Isermann, Berend
    [J]. EUROPEAN HEART JOURNAL, 2023, 44 (40) : 4281 - 4283
  • [2] UTILITY OF PCSK9-INHIBITORS IN DYSLIPIDEMIA AND TYPE 2 DIABETES MELLITUS PATIENTS
    Constantin, Ciprian
    Tudor, Veronica Gabriela
    [J]. INTERDIAB 2017: DIABETES MELLITUS IN INTERNAL MEDICINE, 2017, : 162 - 169
  • [3] A LARGE ITALIAN COHORT ON PCSK9-INHIBITORS: A SINGLE CENTER EXPERIENCE
    Sbrana, F.
    Dal Pino, B.
    Bigazzi, F.
    Ripoli, A.
    Volpi, E.
    Lo Surdo, G.
    Pianelli, M.
    Luciani, R.
    Biagni, S.
    Sampietro, T.
    [J]. ATHEROSCLEROSIS, 2020, 315 : E258 - E258
  • [4] A LARGE ITALIAN COHORT ON PCSK9-INHIBITORS: A SINGLE CENTER EXPERIENCE
    Sbrana, F.
    Dal Pino, B.
    Bigazzi, F.
    Ripoli, A.
    Volpi, E.
    Lo Surdo, G.
    Pianelli, M.
    Luciani, R.
    Biagini, S.
    Sampietro, T.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0G) : G73 - G74
  • [5] Efficacy and safety of PCSK9-Inhibitors in the real-world: data from a clinical registry
    Saba, P. S.
    Murgia, A.
    Gazale, E.
    Terrosu, P.
    Sanna, G. D.
    Parodi, G.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3338 - 3338
  • [6] Identification of patients with systemic lupus erythematosus in administrative healthcare databases
    Hanly, J. G.
    Thompson, K.
    Skedgel, C.
    [J]. LUPUS, 2014, 23 (13) : 1377 - 1382
  • [7] UNDERREPRESENTATION OF OLDER ADULTS IN CLINICAL TRIALS: A CASE STUDY OF PCSK9-INHIBITORS
    Le, J.
    Yasar, S.
    Varadhan, R.
    Li, T.
    [J]. GERONTOLOGIST, 2016, 56 : 148 - 148
  • [8] Sex Differences on Cardiovascular Outcomes of Pcsk9-Inhibitors: A Meta-Analysis
    Rivera, Frederick B.
    De Luna, Deogracias V.
    Ansay, Marie Francesca M.
    Rocimo, Aubrey Melody
    Alfonso, Pia Gabrielle I.
    Ong, Bradley Ashley
    Golbin, Jem Marie P.
    Shah, Nishant
    Volgman, Annabelle Santos
    [J]. CIRCULATION, 2022, 146
  • [9] How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases
    Piccinni, Carlo
    Dondi, Letizia
    Calabria, Silvia
    Ronconi, Giulia
    Pedrini, Antonella
    Lapi, Francesco
    Marconi, Ettore
    Parretti, Damiano
    Medea, Gerardo
    Cricelli, Claudio
    Martini, Nello
    Maggioni, Aldo Pietro
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 371 : 236 - 243
  • [10] Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain
    Cosin-Sales, Juan
    Sidelnikov, Eduard
    Villamayor, Santiago
    Fernandez, Miriam
    Merino-Montero, Sandra
    Zamora, Alberto
    [J]. ADVANCES IN THERAPY, 2023, 40 (06) : 2710 - 2724
12345